Q32 Bio Inc. is a leading biotechnology company with a mission to revolutionize the future of targeted immune therapeutics. Established in 2017, the company is headquartered in the United States. Q32 Bio is dedicated to developing innovative therapeutics that target powerful regulators of the innate and adaptive immune systems, with a focus on the IL-7 pathway and complement system. This targeted approach aims to re-balance the immune system in severe autoimmune and inflammatory diseases, providing new hope for patients facing conditions with limited treatment options. The company's commitment to addressing immune system dysregulation has garnered significant attention, as evidenced by its recent $42.00M Venture Round investment on 25 March 2024. Notable investors in this round include Atlas Venture, Abingworth, OrbiMed, Osage University Partners, Acorn Bioventures, Agent Capital, CU Healthcare Innovation Fund, Sanofi Ventures, Homology Medicines, and Bristol-Myers Squibb.
Q32 Bio Inc.
Revolutionizing the future of targeted immune therapeutics
Waltham, United States
28 employees
Total: $255.50M
Biotechnology, Health Care +1
General Information
Waltham, United States
BounceWatch is an independent company data service, not affiliated with Q32 Bio Inc.. To contact Q32 Bio Inc., visit q32bio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
United States Market
Biotechnology
Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.
Q32 Bio Inc. presented additional results from the SIGNAL-AA trial of bempikibart at #EADV2026 through a late-breaking oral and poster presentation.
Q32 Bio Inc. announced the appointment of José Trevejo, M.D., Ph.D., as their new Chief Medical Officer.
About Q32 Bio Inc.
Taxonomy: immune therapeutics, IL-7 pathway, complement system, autoimmune diseases, inflammatory diseases, immunotherapy, immune system regulation, treatment options, therapeutics development, dysregulation, innovative biotech, immune modulation, precision medicine, startup biotech
Funding Rounds & Investors (7)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Private Placement Non VC | $55.00M | - |
|
01 May 2026 |
| Post-IPO Equity | $10.50M | - |
|
01 Feb 2026 |
| Post-IPO Equity | $42.00M | 8 |
|
01 Mar 2024 |
| IPO | $42.00M | 9 |
|
01 Nov 2023 |
| Series B | $60.00M | 2 |
|
01 Oct 2020 |
| Series A | $46.00M | 5 |
|
01 May 2020 |
| Spinout | Undisclosed | 1 |
|
01 Jan 2017 |
Q32 Bio Inc. Alternatives & Competitors
View All Alternatives
We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases
Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary na...
Regulating Inflammation - through the nervous system
Nuvig Therapeutics Inc.
Georgiamune Inc.
FAQ About Q32 Bio Inc.
Source: BounceWatch company record for Q32 Bio Inc., https://bouncewatch.com/company/q32-bio-inc, updated 29 June 2026. When citing, please name BounceWatch and link this page.
